Details

Autor(en) / Beteiligte

• Wattson, Daniel A., MD
• Tanguturi, Shyam K., MD
• Spiegel, Daphna Y., MD
• Niemierko, Andrzej, PhD
• Biller, Beverly M.K., MD
• Nachtigall, Lisa B., MD
• Bussière, Marc R., MSc
• Swearingen, Brooke, MD
• Chapman, Paul H., MD
• Loeffler, Jay S., MD
• Shih, Helen A., MD

Titel

Outcomes of Proton Therapy for Patients With Functional Pituitary Adenomas

Ist Teil von

• International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (3), p.532-539

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2014

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Purpose/Objective(s) This study evaluated the efficacy and toxicity of proton therapy for functional pituitary adenomas (FPAs). Methods and Materials We analyzed 165 patients with FPAs who were treated at a single institution with proton therapy between 1992 and 2012 and had at least 6 months of follow-up. All but 3 patients underwent prior resection, and 14 received prior photon irradiation. Proton stereotactic radiosurgery was used for 92% of patients, with a median dose of 20 Gy(RBE). The remainder received fractionated stereotactic proton therapy. Time to biochemical complete response (CR, defined as ≥3 months of normal laboratory values with no medical treatment), local control, and adverse effects are reported. Results With a median follow-up time of 4.3 years (range, 0.5-20.6 years) for 144 evaluable patients, the actuarial 3-year CR rate and the median time to CR were 54% and 32 months among 74 patients with Cushing disease (CD), 63% and 27 months among 8 patients with Nelson syndrome (NS), 26% and 62 months among 50 patients with acromegaly, and 22% and 60 months among 9 patients with prolactinomas, respectively. One of 3 patients with thyroid stimulating hormone—secreting tumors achieved CR. Actuarial time to CR was significantly shorter for corticotroph FPAs (CD/NS) compared with other subtypes ( P =.001). At a median imaging follow-up time of 43 months, tumor control was 98% among 140 patients. The actuarial 3-year and 5-year rates of development of new hypopituitarism were 45% and 62%, and the median time to deficiency was 40 months. Larger radiosurgery target volume as a continuous variable was a significant predictor of hypopituitarism (adjusted hazard ratio 1.3, P =.004). Four patients had new-onset postradiosurgery seizures suspected to be related to generously defined target volumes. There were no radiation-induced tumors. Conclusions Proton irradiation is an effective treatment for FPAs, and hypopituitarism remains the primary adverse effect.